MCL1 and acute myeloid leukemia: Third, improved understandings of the biology of AML have contributed to more effective treatments by enabling resistance mechanisms to be targeted upfront (e.g. the use of MCL-1 inhibitors in combination with potent agents that are known to give rise to MCL-1 overexpressing relapses).